Table 1.
Characteristics of 46 melanoma patients.
| All patients n = 46 | CR n = 1 | PR n = 3 | SD n = 14 | PD n = 28 | |
|---|---|---|---|---|---|
| Gender | |||||
| Female | 28 | 1 | 1 | 12 | 14 |
| Male | 18 | 0 | 2 | 2 | 14 |
| Age | 67 (34–89) | 83 | 72 (68–79) | 69 (57–78) | 65 (34–89) |
| Stage | |||||
| I | 0 | 0 | 0 | 0 | 0 |
| II | 11 | 0 | 0 | 5 | 6 |
| III | 21 | 1 | 3 | 7 | 10 |
| IV | 14 | 0 | 0 | 2 | 12 |
Forty-six patients participated. The clinical response was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), based on response evaluation criteria in solid tumors (RECIST, v1.1).